Biologics Portfolio Expansion Pfanstiehl has launched high purity glycine injectable grade excipient and multi compendial glycine designed for biologics, vaccines, and downstream protein purification, signaling readiness to supply key excipients for these segments.

Domestic Manufacturing Reliability US based operations with cGMP compliance and a longstanding history offer supply reliability and regulatory traceability for pharma and biotech customers seeking onshore sourcing.

Biologics and Vaccines Focus Focused on injectable biologics and vaccines including monoclonal antibodies downstream purification, Pfanstiehl aligns with vaccine manufacturers, biotech CDMOs, and contract manufacturers needing HPLE LM excipients.

Cross Sell Portfolio Broad portfolio across carbohydrates, amino acids, and buffer salts enables cross selling to existing customers who want multiple excipients from a single supplier, improving procurement efficiency.

Regulatory Quality Advantage Regulatory and quality emphasis with cGMP USP monographs and low endotoxin and low metals specifications reduces risk for customers and simplifies their quality assurance in the supply chain.